Empagliflozin, metformin and insulin degludec, during pregnancy: a case report
- 211 Downloads
KeywordsPregnancy Diabetes Therapy Metformin Empagliflozin Degludec
Compliance with ethical standards
Conflict of interest
A.C. has received speaker fees and/or consulting honoraria from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi-Aventis, Takeda and has received research grant support from Eli Lilly and Novo Nordisk. G.F. has received speaker fees from Eli Lilly, Merck Sharp & Dohme, Menarini Diagnostics and Servier. F.G. and G.D.D. have received nothing.
The study was in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments.
Informed consent was obtained from the patient included in the case report.
- 4.Highlights of prescribing information, Jardiance n.d. http://docs.boehringer-ingelheim.com/PrescribingInformation/PIs/Jardiance/jardiance.pdf